Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...

A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

A pill version of A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

While disappointing, the failure of these trials was more likely than not, and we are not changing our fair value estimate.

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...